Recurrent extrahepatic papillary cholangiocarcinoma with CCNE1 amplification, TP53 mutation and CNS involvement a capecitabine exceptional response case report

Cholangiocarcinoma (CCA) is a heterogeneous disease; the incidence of brain metastases from CCA ranges from 0.15 % to 1.4 %. We present the case of a 50-year-old woman with recurrent extrahepatic cholangiocarcinoma involving the central nervous system (CNS) and improvement in overall survival (OS). Next-Generation Sequencing (NGS) was performed, revealing CCNE1 amplification and a TP53 mutation. • Biliary cancers brain metastases, are rare, and there is limited information available about. • Median survival of approximately three months. • The CCNE1 amplifications and TP53 mutations has been associated with a decreased chemotherapy response. • The patient stated capecitabine monotherapy reaching an overall survival (OS) of 33 months.